CL2017001773A1 - Análogos de calcitonina para tratar enfermedades y trastornos. - Google Patents

Análogos de calcitonina para tratar enfermedades y trastornos.

Info

Publication number
CL2017001773A1
CL2017001773A1 CL2017001773A CL2017001773A CL2017001773A1 CL 2017001773 A1 CL2017001773 A1 CL 2017001773A1 CL 2017001773 A CL2017001773 A CL 2017001773A CL 2017001773 A CL2017001773 A CL 2017001773A CL 2017001773 A1 CL2017001773 A1 CL 2017001773A1
Authority
CL
Chile
Prior art keywords
disorders
treat diseases
calcitonin analogues
calcitonin
analogues
Prior art date
Application number
CL2017001773A
Other languages
English (en)
Inventor
Morten Karsdal
Kim Henriksen
Kim Vietz Andreassen
Sofie Gydesen
Sara Toftegaard Hjuler
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of CL2017001773A1 publication Critical patent/CL2017001773A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LOS ANÁLOGOS DE CALCITONINA COMO UN MEDICAMENTO PARA PRODUCIR UNA DISMINUCIÓN EN LOS TRIGLICÉRIDOS DEL HÍGADO O PARA REDUCIR LA ACUMULACIÓN DE GRASA EN EL HÍGADO DE UN SUJETO.</p>
CL2017001773A 2015-01-08 2017-07-04 Análogos de calcitonina para tratar enfermedades y trastornos. CL2017001773A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1500263.7A GB201500263D0 (en) 2015-01-08 2015-01-08 Calcitonin analogues for treating diseases and disorders

Publications (1)

Publication Number Publication Date
CL2017001773A1 true CL2017001773A1 (es) 2018-03-09

Family

ID=52597359

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001773A CL2017001773A1 (es) 2015-01-08 2017-07-04 Análogos de calcitonina para tratar enfermedades y trastornos.

Country Status (17)

Country Link
US (2) US10350272B2 (es)
EP (1) EP3247383A1 (es)
JP (1) JP2018502854A (es)
KR (1) KR20170120576A (es)
CN (1) CN107206056A (es)
AU (1) AU2016205994A1 (es)
BR (1) BR112017014552A2 (es)
CA (1) CA2969293A1 (es)
CL (1) CL2017001773A1 (es)
CO (1) CO2017007007A2 (es)
EA (1) EA201791154A1 (es)
GB (1) GB201500263D0 (es)
IL (1) IL253026A0 (es)
MX (1) MX2017008755A (es)
PE (1) PE20171320A1 (es)
PH (1) PH12017500988A1 (es)
WO (1) WO2016110525A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) * 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2026114213A1 (en) * 2024-11-26 2026-06-04 Innovent Biologics (Suzhou) Co., Ltd. Dual amylin and calcitonin receptor agonists and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1608347B1 (en) 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
AU2004317954A1 (en) 2003-09-17 2005-10-13 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (pt) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Sistemas estáveis de nanocápsula para a administração de moléculas activas
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
ES2622877T3 (es) * 2009-01-22 2017-07-07 Keybioscience Ag Tratamiento para la obesidad
CA2854175A1 (en) * 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
BR112016010643A2 (pt) * 2013-11-14 2017-12-05 Keybioscience Ag peptídeo

Also Published As

Publication number Publication date
US20180264085A1 (en) 2018-09-20
PE20171320A1 (es) 2017-09-07
CA2969293A1 (en) 2016-07-14
WO2016110525A1 (en) 2016-07-14
JP2018502854A (ja) 2018-02-01
IL253026A0 (en) 2017-08-31
EP3247383A1 (en) 2017-11-29
AU2016205994A1 (en) 2017-06-15
BR112017014552A2 (pt) 2018-05-15
MX2017008755A (es) 2017-11-17
CN107206056A (zh) 2017-09-26
US20190328843A1 (en) 2019-10-31
KR20170120576A (ko) 2017-10-31
US10350272B2 (en) 2019-07-16
PH12017500988A1 (en) 2017-12-18
GB201500263D0 (en) 2015-02-25
EA201791154A1 (ru) 2017-09-29
CO2017007007A2 (es) 2018-01-31

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
IL257978B (en) Use of pasteurized akkermansia for treating metabolic disorders
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
SV2017005367A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2016002764A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
EA201691582A1 (ru) Новые фармацевтические препараты
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015003140A (es) Formulaciones de enzalutamida.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
MX2017004983A (es) Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
AR100306A1 (es) Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2015011671A (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
CL2016002779A1 (es) Composición para el cuidado de la piel
PH12017500988A1 (en) Calcitonin analogues for treating diseases and disorders
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.